Moisturizer habits of eczema patients under systemic therapy revealed
NCT ID NCT06983561
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 80 adults with moderate-to-severe atopic dermatitis (eczema) whose condition is controlled by systemic treatments. Researchers wanted to understand how these patients use moisturizers and what they expect from them. Participants filled out questionnaires about their skin, habits, and needs. The goal is to improve care by learning more about patient preferences.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
80 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects will be enrolled from the investigator's outpatients reception and/or from the database of the centre. The subjects corresponding to eligibility criteria may receive a phone call, a letter or an e-mail proposing to participate to the clinical study.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Criteria related to the population: * Subject aged between 18 and 75 years included * Subject having signed his/her written informed consent for his/her participation in the study * Subject affiliated to a social security system or health insurance, or is a beneficiary (if required by national regulations * Subject with appropriate hardware (smartphone and/or tablet and/or computer) to complete digital questionnaires * Subject with a mailbox and internet access to create his account to complete digital questionnaires Criteria related to the disease and treatment: • Subject with moderate to severe atopic dermatitis controlled by systemic treatment, meaning: * Using systemic treatment for atopic dermatitis (biologics, janus kinase inhibitors or conventional immunosuppressants) initiated for at least 6 months at the time of the inclusion visit * With an unchanged systemic treatment dose for at least 2 months at the time of the inclusion visit, * And with an vIGA-ADTM ≤ 2 (Mild). Non Inclusion criteria: Criteria related to the population: * Subject unable to understand the information given including study procedures (for linguistic or psychiatric reasons) and to give his/her consent in writing and to report required information in writing in the questionnaire * For woman of childbearing potential: pregnant or breastfeeding or planning to be pregnant during the study * Subject who has forfeited his/her freedom by administrative or legal award or is under guardianship * Subject who, in the judgement of the investigator, is not likely to be compliant with study-related constraints and requirements * Subject who is currently participating, who plans to participate or who has participated within the previous weeks or months in another clinical study liable to interfere with the study assessments according to the investigator's assessment * Subject is in a position likely to represent a conflict of interest and/or is a family member of any people involved in the conduct of the study (secretary, nurse, technician,…), of the investigational site Criteria related to the diseases / skin condition: • Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allergologie et Immunologie Clinique, CHU Lyon Sud
Pierre-Bénite, F-69495, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin scans may predict who responds to dupilumab for eczema
- Can a daily liquid medicine calm severe eczema in toddlers and preschoolers?
- Scientists probe whether lebrikizumab rewires diseased skin at the molecular level
- Can a Lab-Made antibody calm severe eczema?
- Is your nose fueling infected eczema and scabies sores?
- Can an eczema drug reshape the Skin's microbial community?